Lanicemine
 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C13H14N2 |
| Molar mass | 198.269g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lanicemine(AZD6765) is a low-trappingNMDA receptor antagonistthat was underdevelopmentbyAstraZenecafor the management of severe andtreatment-resistant depression.[1][2]Lanicemine differs fromketaminein that it is alow-trappingNMDA receptorantagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects.[3]However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.[4]
See also[edit]
- 4-Chlorokynurenine
- AD-1211
- Apimostinel
- CERC-301
- Diphenidine
- Ephenidine
- Esketamine
- Lefetamine
- Memantine
- Methoxphenidine
- MT-45
- Rapastinel
References[edit]
- ^"Lanicemine".AdisInsight.Retrieved18 June2017.
- ^Machado-Vieira R, Henter ID, Zarate CA (May 2017)."New targets for rapid antidepressant action".Progress in Neurobiology.152:21–37.doi:10.1016/j.pneurobio.2015.12.001.PMC4919246.PMID26724279.
- ^Zarate CA, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, et al. (August 2013)."A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression".Biological Psychiatry.74(4): 257–64.doi:10.1016/j.biopsych.2012.10.019.PMC3594049.PMID23206319.
- ^Flowers S."Return to growth: AstraZeneca's CEO Pascal Soriot says 2013 was year of" momentum "for the company".Retrieved6 February2014.